Related Experiment Videos
Tolerability and safety: essentials in antidepressant pharmacotherapy
1Institute of Psychiatry, University of London, Bethlem Royal, United Kingdom.
The Journal of Clinical Psychiatry
|January 1, 1996
Summary
Nefazodone demonstrates efficacy comparable to other antidepressants but offers a distinct safety and tolerability profile. This antidepressant may be a suitable option due to its favorable adverse-event profile and potential anxiolytic effects.
Area of Science:
- Pharmacology
- Neuroscience
- Clinical Psychiatry
Background:
- Current antidepressants exhibit similar efficacy rates (60-80% response), but vary significantly in side effect profiles and toxicity.
- Tricyclic antidepressants (TCAs) are associated with dry mouth, while serotonin selective reuptake inhibitors (SSRIs) commonly cause nausea.
- The choice of antidepressant is primarily dictated by tolerability and safety due to gradual clinical response and difficulty in discerning differential response factors.
Purpose of the Study:
- To evaluate the efficacy and safety of nefazodone, a unique antidepressant with dual actions on the serotonin system.
- To compare the adverse event profile of nefazodone with TCAs, SSRIs, and placebo.
- To assess the tolerability and potential anxiolytic properties of nefazodone.
Main Methods:
- Analysis of safety data from approximately 3,500 patients across all research trials, including controlled trials comparing nefazodone with TCAs, SSRIs, and placebo.
- Evaluation of adverse experiences reported in controlled trials.
- Assessment of long-term safety data from nearly 1,300 patients and evaluation in normal subjects for impairment and alcohol interaction.
Main Results:
- Nefazodone's most frequent adverse experiences compared to placebo included nausea (21% vs. 14%), somnolence (19% vs. 13%), and dry mouth (19% vs. 13%).
- Dropout rates due to adverse experiences were approximately 12% for nefazodone, compared to 7.4% for placebo, 10.4% for SSRIs, and 21.8% for imipramine (a TCA).
- Long-term safety data indicated nefazodone was well tolerated, produced less impairment than imipramine, and had a lower likelihood of alcohol interaction.
Conclusions:
- Nefazodone possesses a favorable adverse-event profile compared to TCAs and a distinct profile from SSRIs.
- Nefazodone appears to be safe and well-tolerated in both acute and long-term use.
- Its unique pharmacological actions, including 5-HT2 antagonism, may contribute to anxiolytic effects and a potentially improved tolerability.